Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02117037

Enrollment

180

Registered

2014-04-17

Start date

2014-06-01

Completion date

2018-08-01

Last updated

2026-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndromes

Brief summary

This prospective study aimed to validate a new prognostic approach of endothelial progenitor cells associated biomarkers in patients with acute coronary syndromes . Recruitment is made prospectively by two centers of Inter -region South Mediterranean,

Interventions

OTHERblood sample

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* acute coronary syndrome (ST + \< 12 hours and ST- high risk or intermediate risk ),which there is an indication of percutaneous coronary intervention.

Exclusion criteria

* Cancer * Chronic inflammatory disease * Infectious disease * Erythrocyte \<4 G/l * Thrombopénia less than 100 000/mm3 ;

Design outcomes

Primary

Measure	Time frame
evaluate the value of circulating endothelial progenitor cells quantification in the initial phase of ACS in predicting the occurrence of a major cardiovascular event (ECVM ) at 1 year.	one year

Secondary

Measure	Time frame
determine the technical characteristics (sensitivity and specificity) and predictive value of the number of PEC	one day , one month , one year

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 9, 2026